The hematologist and oncologist from University of California, San Francisco discussed the current state of cellular therapy in multiple myeloma.
The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.
Lineage Cell Therapeutics announced promising data from interim results of the phase 1/2a clinical trial assessing the cell therapy.
The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.
Review top news and interview highlights from the week ending September 17, 2021.